Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease

Pediatric Nephrology

Volumn 24, Issue 4, 2009, Pages 815-821

  Hanafy, Sherif ^a   Pinsk, Maury ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotension; Calcium channel blockers; Hypertension; Obesity; Pharmacotherapy; Renal disease dysfunction

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CORTICOSTEROID; ENALAPRIL; LOSARTAN; NIFEDIPINE; PREDNISONE; RAMIPRIL;

ACUTE GLOMERULONEPHRITIS; ADOLESCENT; ANAPHYLACTOID PURPURA; ARTICLE; BLADDER DYSFUNCTION; CHILD; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEMATURIA; HUMAN; HYPERTENSION; INFANT; KIDNEY DISEASE; MALE; MEDICAL RECORD REVIEW; OBESITY; PRIORITY JOURNAL; REFLUX NEPHROPATHY; SYSTOLIC BLOOD PRESSURE; URINARY TRACT DISEASE;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; OBESITY; RETROSPECTIVE STUDIES;

EID: 61549125382     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-1064-y     Document Type: Article

References (43)

1. Spurgeon D (2002) Childhood obesity in Canada has tripled in past 20 years. Br Med J 324:1416
2. Ogden CL, Carroll MD, Flegal KM (2003) Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 32:741-760
3. Ogden CL, Flegal KM, Carroll MD, Johnson CL (2002) Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288:1728-1732
4. Tremblay MS, Willms JD (2000) Secular trends in the body mass index of Canadian children. Can Med Assoc J 163:1429-1433
5. Hanevold CD, Ho PL, Talley L, Mitsnefes MM (2005) Obesity and renal transplant outcome: A report of the North American pediatric renal transplant cooperative study. Pediatrics 115:352-356
6. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D (2007) Assessment of child and adolescent overweight and obesity. Pediatrics 120[Suppl 4]:S193-228
7. Sbarbati A, Osculati F, Silvagni D, Benati D, Galie M, Camoglio FS, Rigotti G, Maffeis C (2006) Obesity and inflammation: Evidence for an elementary lesion. Pediatrics 117:220-223
8. Das UN (2001) Is obesity an inflammatory condition? Nutrition 17:953-966
9. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135
10. Visser M (2001) Higher levels of inflammation in obese children. Nutrition 17:480-481
11. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (2001) Low-grade systemic inflammation in overweight children. Pediatrics 107:E13
12. Reinehr T, Stoffel-Wagner B, Roth CL, Andler W (2005) High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. Metabolism 54:1155-1161
13. Hanafy S, Dagenais NJ, Dryden WF, Jamali F (2008) Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. Br J Pharmacol 153:90-99
14. Sattari S, Dryden WF, Eliot LA, Jamali F (2003) Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. Br J Pharmacol 139:945-954
15. Abernethy DR, Schwartz JB (1988) Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol 11:209-215
16. Mayo PR, Skeith K, Russell AS, Jamali F (2000) Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605-613
17. Neuhaus TJ, Ruth EM, Kemper M (2007) Obesity and other clinical endpoints in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 22:471; author's reply 22:472-473
18. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS (1974) The nephrotic syndrome: A complication of massive obesity. Ann Intern Med 81:440-447
19. Hadtstein C, Schaefer F (2008) Hypertension in children with chronic kidney disease: Pathophysiology and management. Pediatr Nephrol 23:363-371
20. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99:2079-2084
21. Flynn JT, Pasko DA (2000) Calcium channel blockers: Pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15:302-316
22. von Vigier RO, Franscini LM, Bianda ND, Pfister R, Casaulta Aebischer C, Bianchetti MG (2001) Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens 15:387-391
23. Seeman T, Dusek J, Vondrak K, Flogelova H, Geier P, Janda J (2004) Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am J Hypertens 17:415-420
24. American Medical Association (2006) Physician ICD-9-CM 2006: International Classification of Diseases, 9th revision. Clinical modification. American Medical Association, Chicago
25. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000) CDC growth charts: United States. Adv Data:1-27
26. Task Force Report on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576
27. National High Blood Pressure Education Program (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 98:649-658
28. Campbell M (2004) Multiple logistic regression models - what are they? Midwifery 20:236-239
29. Abernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E (1986) Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. Ann Intern Med 105:329-336
30. Garanty-Bogacka B, Syrenicz M, Syrenicz A, Gebala A, Lulka D, Walczak M (2005) Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuro Endocrinol Lett 26:242-246
31. Foster BJ, Shults J, Zemel BS, Leonard MB (2006) Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 21:973-980
32. Walker BR, Edwards CR (1994) New mechanisms for corticosteroid-induced hypertension. Br Med Bull 50:342-355
33. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA (1992) Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 19:567-574
34. Erzen B, Sabovic M, Poredos P, Sebestjen M, Keber I, Simcic S (2006) Inflammation markers in young post-myocardial patients exhibiting various expressions of classic coronary risk factors. Coron Artery Dis 17:325-330
35. Mann DL (2002) Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 91:988-998
36. Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL (1975) Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 55:1182-1189
37. Keller F, Maiga M, Neumayer HH, Lode H, Distler A (1984) Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 9:275-282
38. Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A (1984) Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol 17:423-431
39. Clements JD, Jamali F (2007) Pravastatin reverses the down-regulating effect of inflammation on beta-Adrenergic receptors: A disease-drug interaction between inflammation, pravastatin, and propranolol. Vascul Pharmacol 46:52-59
40. Daneshtalab N, Lewanczuk RZ, Russell A, Jamali F (2004) Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. J Clin Pharmacol 44:245-252
41. Daneshtalab N, Lewanczuk RZ, Russell AS, Jamali F (2006) Drug-disease interactions: Losartan effect is not downregulated by rheumatoid arthritis. J Clin Pharmacol 46:1344-1355
42. Dagenais NJ, Jamali F (2005) Protective effects of angiotensin II interruption: Evidence for antiinflammatory actions. Pharmacotherapy 25:1213-1229
43. Robinson RF, Nahata MC, Batisky DL, Mahan JD (2005) Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs 7:27-40